321 related articles for article (PubMed ID: 23076356)
1. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer.
Chugh R; Sangwan V; Patil SP; Dudeja V; Dawra RK; Banerjee S; Schumacher RJ; Blazar BR; Georg GI; Vickers SM; Saluja AK
Sci Transl Med; 2012 Oct; 4(156):156ra139. PubMed ID: 23076356
[TBL] [Abstract][Full Text] [Related]
2. Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer.
Banerjee S; Modi S; McGinn O; Zhao X; Dudeja V; Ramakrishnan S; Saluja AK
Clin Cancer Res; 2016 Jan; 22(2):415-25. PubMed ID: 26405195
[TBL] [Abstract][Full Text] [Related]
3. Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F.
Oliveira A; Beyer G; Chugh R; Skube SJ; Majumder K; Banerjee S; Sangwan V; Li L; Dawra R; Subramanian S; Saluja A; Dudeja V
Lab Invest; 2015 Jun; 95(6):648-659. PubMed ID: 25893635
[TBL] [Abstract][Full Text] [Related]
4. Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.
Modi S; Kir D; Giri B; Majumder K; Arora N; Dudeja V; Banerjee S; Saluja AK
J Gastrointest Surg; 2016 Jan; 20(1):13-23; discussion 23-4. PubMed ID: 26503259
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer.
Arora N; Alsaied O; Dauer P; Majumder K; Modi S; Giri B; Dudeja V; Banerjee S; Von Hoff D; Saluja A
PLoS One; 2017; 12(2):e0171827. PubMed ID: 28192510
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug.
Rivard C; Geller M; Schnettler E; Saluja M; Vogel RI; Saluja A; Ramakrishnan S
Gynecol Oncol; 2014 Nov; 135(2):318-24. PubMed ID: 25172764
[TBL] [Abstract][Full Text] [Related]
7. Minnelide reduces tumor burden in preclinical models of osteosarcoma.
Banerjee S; Thayanithy V; Sangwan V; Mackenzie TN; Saluja AK; Subramanian S
Cancer Lett; 2013 Jul; 335(2):412-20. PubMed ID: 23499892
[TBL] [Abstract][Full Text] [Related]
8. Primary and liver metastasis-derived cell lines from KrasG12D; Trp53R172H; Pdx-1 Cre animals undergo apoptosis in response to triptolide.
Sangwan V; Banerjee S; Jensen KM; Chen Z; Chugh R; Dudeja V; Vickers SM; Saluja AK
Pancreas; 2015 May; 44(4):583-9. PubMed ID: 25875797
[TBL] [Abstract][Full Text] [Related]
9. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer.
Nomura A; McGinn O; Dudeja V; Sangwan V; Saluja AK; Banerjee S
Mol Cancer; 2015 Nov; 14():200. PubMed ID: 26597727
[TBL] [Abstract][Full Text] [Related]
10. Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
Isharwal S; Modi S; Arora N; Uhlrich C; Giri B; Barlass U; Soubra A; Chugh R; Dehm SM; Dudeja V; Saluja A; Banerjee S; Konety B
Prostate; 2017 May; 77(6):584-596. PubMed ID: 28144973
[TBL] [Abstract][Full Text] [Related]
11. miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death.
Chen Z; Sangwan V; Banerjee S; Mackenzie T; Dudeja V; Li X; Wang H; Vickers SM; Saluja AK
Mol Cancer; 2013 Sep; 12(1):105. PubMed ID: 24025188
[TBL] [Abstract][Full Text] [Related]
12. Triptolide induces the expression of miR-142-3p: a negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation.
MacKenzie TN; Mujumdar N; Banerjee S; Sangwan V; Sarver A; Vickers S; Subramanian S; Saluja AK
Mol Cancer Ther; 2013 Jul; 12(7):1266-75. PubMed ID: 23635652
[TBL] [Abstract][Full Text] [Related]
13. Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma.
Caicedo-Granados E; Lin R; Fujisawa C; Yueh B; Sangwan V; Saluja A
Oral Oncol; 2014 Dec; 50(12):1149-56. PubMed ID: 25311433
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia.
Giri B; Gupta VK; Yaffe B; Modi S; Roy P; Sethi V; Lavania SP; Vickers SM; Dudeja V; Banerjee S; Watts J; Saluja A
J Transl Med; 2019 May; 17(1):163. PubMed ID: 31109340
[TBL] [Abstract][Full Text] [Related]
15. Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line.
Kim ST; Kim SY; Lee J; Kim K; Park SH; Park YS; Lim HY; Kang WK; Park JO
BMC Cancer; 2018 Nov; 18(1):1103. PubMed ID: 30419860
[TBL] [Abstract][Full Text] [Related]
16. Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model.
Ding X; Zhou X; Zhang H; Qing J; Qiang H; Zhou G
Cancer Chemother Pharmacol; 2012 Jan; 69(1):253-61. PubMed ID: 21713446
[TBL] [Abstract][Full Text] [Related]
17. Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer.
Modi S; Giri B; Gupta VK; Lavania S; Sethi V; Sharma NS; Pandey S; Vickers S; Dudeja V; Saluja AK
Cancer Lett; 2022 Jul; 537():215591. PubMed ID: 35398530
[TBL] [Abstract][Full Text] [Related]
18. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
[TBL] [Abstract][Full Text] [Related]
19. Triptolide and Its Derivatives as Cancer Therapies.
Noel P; Von Hoff DD; Saluja AK; Velagapudi M; Borazanci E; Han H
Trends Pharmacol Sci; 2019 May; 40(5):327-341. PubMed ID: 30975442
[TBL] [Abstract][Full Text] [Related]
20. Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1.
Banerjee S; Sangwan V; McGinn O; Chugh R; Dudeja V; Vickers SM; Saluja AK
J Biol Chem; 2013 Nov; 288(47):33927-33938. PubMed ID: 24129563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
